Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
1. A method for treating a posterior eye disease in a patient in need thereof, the method comprising administering to the eye of the patient an ophthalmic composition comprising: a therapeutically effective amount of a Glucocorticoid Derivative (GD) comprising an acyl group linked to C 17 , C 21 , or combination thereof via an ester linkage, and a viscosity-inducing component.
2. The method of claim 1 , wherein the posterior eye disease comprises age-related macular degeneration (ARMD), diabetic macular edema, proliferative diabetic retinopathy, uveitis, ocular tumors, glaucoma, or combinations thereof.
3. The method of claim 1 , wherein the administrating is periocular.
4. The method of claim 3 , wherein the administrating is to a suprachoroidal region or suprachoroidal space.
5. The method of claim 1 , wherein the administrating is intravitreal.
6. The method of claim 1 , wherein the viscosity-inducing component comprises hyaluronic acid, carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextrin, polysaccharides, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, derivatives thereof and mixtures thereof.
7. The method of claim 6 , wherein the viscosity-inducing component comprises a polymeric hyaluronate component.
8. The method of claim 1 , wherein the ophthalmic composition has an aqueous solubility less than 10 mg/ml.